Samples | Subgroups | N | Genotype (%) | P1 | P2 | ||
---|---|---|---|---|---|---|---|
 |  |  | T | T/C | C |  |  |
Control | Â | 229 | 70 (31%) | 114 (50%) | 45 (20%) | Â | Â |
METH | Latency of Psychosis | Â | Â | Â | Â | Â | Â |
 |    < 3 years | 64 | 15 (23%) | 32 (50%) | 17 (27%) | 0.366 |  |
 |    ≥ 3 years | 70 | 17 (24%) | 30 (43%) | 23 (33%) | 0.068 | 0.663 |
 | Prognosis of Psychosis |  |  |  |  |  |  |
 |    Transient (< 1 month) | 91 | 21 (23%) | 40 (44%) | 30 (33%) | 0.036 |  |
 |    Prolonged (≥ 1 month) | 56 | 11 (20%) | 34 (61%) | 11 (20%) | 0.231 | 0.115 |
 | Spontaneous Relapse |  |  |  |  |  |  |
 |    Not present | 104 | 22 (21%) | 50 (48%) | 32 (31%) | 0.046 |  |
 |    Present | 60 | 12 (20%) | 31 (52%) | 17 (28%) | 0.167 | 0.905 |
 | Multiple Drug Usage |  |  |  |  |  |  |
 |    None (METH use only) | 52 | 6 (12%) | 29 (56%) | 17 (33%) | 0.0099 |  |
 |    Poly-drugs | 112 | 26 (23%) | 54 (48%) | 32 (29%) | 0.127 | 0.214 |